U.S. Medical Marijuana Market worth over USD 8 billion by 2024: Global Market Insights, Inc.
17 sept. 2018 06h15 HE
|
Global Market Insights, Inc
Sellbyville, Delaware, Sept. 17, 2018 (GLOBE NEWSWIRE) -- The U.S. Medical Marijuana Market is poised to surpass USD 8.0 billion by 2024; according to a new research study published by Global...
CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement
05 sept. 2018 08h57 HE
|
CURE Pharmaceutical
LOS ANGELES, Sept. 05, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), (“CURE”), an innovative drug delivery and development company, today announced that it entered into a multi-year...
Medical Marijuana Market worth over $55 billion by 2024: Global Market Insights, Inc.
22 août 2018 07h00 HE
|
Global Market Insights, Inc
Sellbyville, Delaware, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Global Medical Marijuana Market outlook is projected to surpass USD 55 billion by 2024, says a new Global Market Insights, Inc. report...
Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)
09 avr. 2018 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, April 09, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...
Rhizen Pharmaceuticals S.A. announces clinical data presentations for Tenalisib (RP6530) in R/R T-cell lymphoma at the upcoming 10th Annual T-Cell Lymphoma Forum in La Jolla, CA, USA
29 janv. 2018 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated clinical data for Tenalisib (RP6530), the company’s highly selective and...
Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for RP6530 (tenalisib), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL)
09 déc. 2017 08h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for...
Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USA
05 déc. 2017 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated data for RP6530 (tenalisib), the Company’s highly selective and orally...
Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell Lymphoma
22 sept. 2015 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. has announced the initiation of Phase 2 study of RV1001, a novel, oral selective inhibitor of PI3K...